STAT1d
There is no ‘amyloid cabal’ in Alzheimer’s research
There exists no ‘amyloid cabal’” in Alzheimer’s research, neurologist Dennis Selkoe writes in response to Charles Piller’s ...
Biogen receives Market Perform rating at Bernstein ahead of earnings
Biogen (BIIB) stock was granted a Market Perform recommendation by Bernstein ahead of Q4 earnings, citing concerns over its Alzheimer's drug sales. Read more here.
InMed Pharmaceuticals: InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary ...
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and ...
pharmaphorum2d
Alnylam showcases long-acting amyloid drug at AAIC
With the first amyloid-targeting drug now approved for Alzheimer’s disease, Alnylam has presented preliminary clinical results with a new candidate that could potentially be dosed as ...
ushmm.org4d
Origins of Neo-Nazi and White Supremacist Terms and Symbols
The eruption of neo-Nazism and White Supremacy across the country has exposed the public to symbols, terms, and ideology drawn directly from Nazi Germany and Holocaust-era fascist movements. The ...